Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.

After a string of pipeline failures, Vical has called in advisers to help decide the future of the company.

A capsaicin-based therapy developed by University of Wyoming scientists showed promise in mouse models of obesity.

Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.

Novartis will take MOR106 forward in atopic dermatitis and other indications, handing over up to €850 million in milestones as it goes.

The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology candidates.

IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre, which expects to advance its lead asset into phase 1 next year.

A startup from Johns Hopkins launched with $36 million to bring a potentially disease-modifying drug into phase 1 for Parkinson’s disease.

The pair will start three new trials in the third quarter, including a phase 2 pilot study in CDKL5 deficiency disorder and duplication 15q syndrome.

A new “venture philanthropy” accelerator is offering over $30 million in grants for new biomarkers and diagnostic tests for Alzheimer’s disease.